Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial

Abstract Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC) to improve rifaximin efficacy. In a...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Gabriela Leite, Ali Rezaie, Walter Morales, Stacy Weitsman, Juliana de Freitas Germano, Gillian M. Barlow, Gonzalo Parodi, Maya L. Pimentel, Maria Jesus Villanueva-Millan, Maritza Sanchez, Sarah Ayyad, Ruchi Mathur, Mark Pimentel
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Nature Portfolio 2024-08-01
Rangatū:	Scientific Reports
Ngā marau:	Irritable bowel syndrome Diarrhea-predominant Rifaximin N-acetylcysteine Rat model Bacterial overgrowth
Urunga tuihono:	https://doi.org/10.1038/s41598-024-69162-4
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!